One-Time CRISPR Gene-Editing Therapy Shows Lasting Ability to Safely Lower Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human Phase 1 clinical trial conducted by researchers at the Cleveland Clinic has found that a single infusion of an experimental CRISPR-Cas9 gene-editing therapy produced lasting, significant reductions in…